DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)

by | Aug 2, 2023 | 0 comments

DTx Pharma, a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotides (FALCON™) platform, today announced that the FDA has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).

About FDA Orphan Drug Status

Orphan Drug status refers to a special designation granted to pharmaceutical products that are developed to treat rare diseases or conditions. In many countries, including the United States, the European Union, and Japan, orphan drug status provides certain incentives and benefits to pharmaceutical companies to encourage the development of therapies for rare diseases. These incentives may include extended market exclusivity, tax credits, fee waivers, and assistance with the drug approval process. The intention is to promote the development of treatments for diseases that affect a relatively small number of people and may not be financially viable for pharmaceutical companies to pursue without such incentives. To qualify for orphan drug status, a medication must meet specific criteria defined by regulatory authorities, such as having a prevalence below a certain threshold in the population. Once granted orphan drug status, the pharmaceutical company may receive assistance and incentives to facilitate the development and commercialization of the drug, ultimately benefiting patients with rare diseases.

About DTx-1252

DTx-1252 is a potential first-in-class FALCON™ siRNA therapeutic for treatment of CMT1A. By repressing PMP22, DTx-1252 reverses CMT1A in a mouse model that faithfully recapitulates the genetic and clinical manifestations of the disease. DTx-1252 treatment induces remyelination of axons to normal levels, improves relevant electrophysiological measurements and increases muscle mass, grip strength, coordination and agility in preclinical studies.

Important Steps to take!

If you have a confirmed genetic diagnosis of CMT1A, now is the time to make sure you are in HNF’s Global Registry for Inherited Neuropathies and upload your genetic report.

Join GRIN

If you do not have a confirmed genetic diagnosis of CMT1A, now is the time to make an appointment with the CMT Genie to pursue a genetic diagnosis.

Make an appointment with the CMT Genie

Learn more on this topic

Related Blog Posts

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

HNF and Wave Skater form a Partnership

I (Allison Moore)  is amazed how life moves in such wondrous ways. My family has the good fortune to spend summers at a beautiful Long Island beach where my husband and boys enjoy riding the waves on boogie boards.

HNF-WVU-NIOSH Study update:

We are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”

Dr. Robert Baloh Answers Our Questions About iPS Cell Research

Big news is happening on a cellular level at Cedars-Sinai Medical Center’s Regenerative Medicine Institute in Los Angeles, CA.  Robert H. Baloh, MD PhD, Director of Neuromuscular Medicine, in conjunction with Patrick D. Lyden, MD Neurology Dept. Chair, and Clive Svendsen, PhD, Institute Director, are studying disorders that start in nerve cells. 

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news